A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S
- 25 Oct 2016 Results of a post-hoc analysis assessing the effect of vortioxetine on cognitive functioning and depressive symptoms from 5 studies, published in the Journal of Clinical Psychiatry.
- 22 Mar 2012 This trial is recruting in Finland and France.
- 22 Mar 2012 Planned number of patients changed from 250 to 650 as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History